Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients

Nephrology

Volumn 17, Issue 3, 2012, Pages 225-229

  Ikee, Ryota ^a   Tsunoda, Masataka ^a   Sasaki, Naomi ^a   Sato, Naritsugu ^a   Hashimoto, Nobuo ^a  

^a H N Medic Kitahiroshima ^*  (Japan)

Author keywords

chronic kidney disease mineral bone disorder; erythropoiesis stimulating agent; haemodialysis; renal anaemia; sevelamer

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CARBONATE; CINACALCET; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; VITAMIN D DERIVATIVE;

ADULT; AGED; ANURIA; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DIABETES MELLITUS; DRUG RESPONSE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; IRON THERAPY; MALE; MINERAL BONE DISORDER; PRIORITY JOURNAL;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; POLYAMINES; RENAL DIALYSIS; VITAMIN D;

EID: 84857565439     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01545.x     Document Type: Article

References (21)

1. Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP,. Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int. 2010; 78 (Suppl 117): S10-21.
2. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther. Apher. Dial. 2008; 12: 514-25.
3. Aasebo W, Hartmann A, Jenssen T,. Predictors of anemia in patients on hemodialysis. Hemodial. Int. 2009; 13: 335-9.
4. Locatelli F, Pisoni RL, Combe C, et al,. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2004; 19: 121-32. (Pubitemid 38072623)
5. Portoles J, Lopez-Gomez JM, Aljama PA,. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: The MAR Study. Nephrol. Dial. Transplant. 2007; 22: 500-7. (Pubitemid 46189895)
6. Akizawa T, Pisoni RL, Akiba T, et al,. Japanese haemodialysis anaemia management practices and outcomes (1999-2006): Results from the DOPPS. Nephrol. Dial. Transplant. 2008; 23: 3643-53.
7. Gunnell J, Yeun JY, Depner TA, Kaysen GA,. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. 1999; 33: 63-72. (Pubitemid 29031210)
8. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD,. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am. J. Kidney Dis. 2003; 42: 761-73. (Pubitemid 37187377)
9. Tolman C, Richardson D, Bartlett C, Will E,. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: A randomized clinical study. J. Am. Soc. Nephrol. 2005; 16: 1463-70. (Pubitemid 41716532)
10. Kainz A, Mayer B, Kramar R, Oberbauer R,. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol. Dial. Transplant. 2010; 25: 3701-6.
11. Penne EL, van der Weerd NC, Grooteman MP, et al,. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2011; 6: 281-9.
12. Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A,. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: Review of causes and management. Blood Purif. 2010; 29: 1-12.
13. Tsubakihara Y, Nishi S, Akiba T, et al,. 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. Ther. Apher. Dial. 2010; 14: 240-75.
14. Caglar K, Yilmaz MI, Saglam M, et al,. Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 61-8.
15. Takei T, Otsubo S, Uchida K, et al,. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin. Pract. 2008; 108: c278-83. (Pubitemid 351704301)
16. Peres AT, Dalboni MA, Canziani ME, et al,. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodial. Int. 2009; 13: 271-7.
17. Stinghen AE, GonA̧alves SM, Bucharles S, et al,. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif. 2010; 29: 352-6.
18. Koiwa F, Kazama JJ, Tokumoto A, et al,. ROD21 Clinical Research Group. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther. Apher. Dial. 2005; 9: 336-9. (Pubitemid 41800805)
19. Brandenburg VM, Schlieper G, Heussen N, et al,. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: A prospective study. Nephrol. Dial. Transplant. 2010; 25: 2672-9.
20. Kilpatrick RD, Critchlow CW, Fishbane S, et al,. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 1077-83.
21. Means RT Jr, Krantz SB,. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J. Clin. Invest. 1993; 91: 416-19. (Pubitemid 23064122)